Pfizer and Mylan are betting that combining Pfizer’s off-patent business, called Upjohn, with Mylan—known for the EpiPen emergency allergy shot—will provide a pathway to reignite sales growth. Shareholders of Pfizer will own 57% of the new business and the rest… Read More ›
Pfizer Inc. (PFE). Shares have underperformed during the past three years, rising 9.4% compared to the S&P 500’s rise of nearly 31%. The pharmaceutical company now appears to be poised to rise 10% in the coming weeks, based on technical analysis.
StockMarketNews.Today – Pfizer has not only underperformed the broader stock market, but its valuation is among the cheapest of some of the other big pharmaceuticals. Shares of Pfizer are trading at just 11.9 times 2019 earnings estimates, well below that of the S&P 500 and companies like Merck & Co. Inc.